BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 16988466)

  • 1. Assuring the quality, safety, and efficacy of DNA vaccines.
    Robertson JS; Griffiths E
    Methods Mol Med; 2006; 127():363-74. PubMed ID: 16988466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assuring the quality, safety, and efficacy of DNA vaccines.
    Robertson JS; Griffiths E
    Mol Biotechnol; 2001 Feb; 17(2):143-9. PubMed ID: 11395863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assuring the quality, safety, and efficacy of DNA vaccines.
    Robertson JS; Griffiths E
    Methods Mol Med; 2000; 29():499-508. PubMed ID: 21374344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation and review of DNA vaccine products.
    Smith HA
    Dev Biol (Basel); 2000; 104():57-62. PubMed ID: 11713825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Food and Drug Administration regulation and evaluation of vaccines.
    Marshall V; Baylor NW
    Pediatrics; 2011 May; 127 Suppl 1():S23-30. PubMed ID: 21502242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ensuring the optimal safety of licensed vaccines: a perspective of the vaccine research, development, and manufacturing companies.
    Kanesa-thasan N; Shaw A; Stoddard JJ; Vernon TM
    Pediatrics; 2011 May; 127 Suppl 1():S16-22. PubMed ID: 21502248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European Union guidance on the quality, safety and efficacy of DNA vaccines and regulatory requirements.
    Robertson JS; Cichutek K
    Dev Biol (Basel); 2000; 104():53-6. PubMed ID: 11713824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and approval of vaccines in the United States.
    Botstein P
    Isr J Med Sci; 1986; 22(3-4):268-71. PubMed ID: 3528047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trials performed for the new drug approval process in the United States: standard methods and alternative methods.
    Browne TR
    Epilepsy Res Suppl; 1993; 10():31-44. PubMed ID: 8251105
    [No Abstract]   [Full Text] [Related]  

  • 10. New vaccine technologies.
    Wood DJ
    Dev Biol (Basel); 2002; 111():285-90. PubMed ID: 12678251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration.
    Ball R; Horne D; Izurieta H; Sutherland A; Walderhaug M; Hsu H
    Pediatrics; 2011 May; 127 Suppl 1():S31-8. PubMed ID: 21502249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA vaccines: safety aspect assessment and regulation.
    Medjitna TD; Stadler C; Bruckner L; Griot C; Ottiger HP
    Dev Biol (Basel); 2006; 126():261-70; discussion 327. PubMed ID: 17058502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges associated with the development, manufacturing, and delivery of cellular medicines.
    Preti RA
    Cancer J; 2001; 7 Suppl 2():S62-6. PubMed ID: 11777266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons from preventive infectious disease vaccines.
    Chandler DK; Midthun K; Goldenthal KL
    Dev Biol (Basel); 2004; 116():61-6; discussion 69-76. PubMed ID: 15603184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and standardisation of DNA vaccines.
    Cichutek K
    Dev Biol Stand; 1999; 100():119-29. PubMed ID: 10616182
    [No Abstract]   [Full Text] [Related]  

  • 17. The domestic drug regulatory process: why time is of the essence.
    Katz R
    Epilepsy Res Suppl; 1993; 10():91-106. PubMed ID: 8251109
    [No Abstract]   [Full Text] [Related]  

  • 18. Chapter 22: Assuring the quality, safety and efficacy of HPV vaccines: the scientific basis of regulatory expectations pre- and post-licensure.
    Wood D; Shin JH; Duval B; Schmitt HJ
    Vaccine; 2006 Aug; 24 Suppl 3():S3/187-92. PubMed ID: 16950006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventive medicines: vaccination, prophylaxis of infectious diseases, disinfectants.
    Heininger U
    Handb Exp Pharmacol; 2011; 205():317-37. PubMed ID: 21882119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.